Johnson & Johnson has shared new longer-term findings from the Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody that targets both the epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy for patients with RAS/BRAF wild-type metastatic colorectal cancer. The data demonstrated encouraging anti-tumor activity, sustained responses over time, and low rates of treatment-related discontinuation. These results support the continued evaluation of this treatment approach in ongoing Phase 3 studies for first- and second-line colorectal cancer. The findings were presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in Abstract #166.

Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India

Dr. Filippo Pietrantonio, M.D., Head of the Gastrointestinal Oncology Unit at the IRCCS Foundation, National Cancer Institute in Milan, Italy, explained that the study results highlight the potential for amivantamab combined with chemotherapy to provide meaningful and long-lasting benefits for patients with advanced colorectal cancer. He noted that even patients with liver metastases, who traditionally face poorer outcomes, were able to maintain responses for extended periods, with some exceeding two years. He described this as a significant step forward in a disease where achieving sustained efficacy has historically been difficult.

Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk

Colorectal cancer is the third most commonly diagnosed cancer worldwide and remains a leading cause of cancer-related deaths. While it is more common in older adults, cases among individuals under 50 are increasing. More than half of patients with colorectal cancer eventually develop metastatic disease, with liver involvement occurring in roughly 70 percent of cases. Resistance to current first-line therapies often emerges early, limiting the duration of benefit for patients. For those with RAS/BRAF wild-type metastatic colorectal cancer who experience disease progression, second-line treatment options are limited. Historical response rates to EGFR inhibitors combined with chemotherapy range from 32 to 36 percent, with median progression-free survival of just over five to six months. Research has indicated that alterations in MET are a frequent cause of resistance to EGFR-targeted therapies, underscoring the need for treatment strategies that simultaneously target both EGFR and MET pathways.

These new findings from the OrigAMI-1 study provide early but meaningful evidence that combining amivantamab with chemotherapy could represent a promising approach for improving outcomes in this patient population and support further investigation in larger Phase 3 trials.

Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com